SanjalHimanshuDesaiMD

Physician

Dr. Desai is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

MT2022-60: Ph 2 Study of Pembro+ BEAM With ASCT for Relapsed Hodgkin Lymphoma Start of enrollment: 2024 Aug 01
Not yet recruiting
Phase 2
Roles: Contact

PubMed

Phase 2 study of alemtuzumab and dose-adjusted EPOCH-R in relapsed or refractory aggressive B-cell lymphomas.
Rahul Lakhotia, Christopher Melani, Kieron Dunleavy, Stefania Pittaluga, Sanjal Desai
Leukemia & Lymphoma. 2025-02-03
1 citations
Cardiovascular Considerations After Cancer Therapy: Gaps in Evidence andExpert Panel Recommendations.
Anne Blaes, Anju Nohria, Saro Armenian, Carmen Bergom, Paaladinesh Thavendiranathan
JACC. Cardiooncology. 2025-01-01
3 citations
Overall survival of patients with cHL who progress after autologous stem cell transplant: results in the novel agent era.
Sanjal H Desai, Michael A Spinner, Andrew M Evens, Alice Sykorova, Veronika Bachanova
Blood Advances. 2023-12-12

Abstracts/Posters

Prevalence of Chronic Kidney Disease (CKD) in Lymphoma Survivors
Sanjal Desai, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Phase 2 Study of Alemtuzumab Added to Dose-Adjusted EPOCH-R in Relapsed and Refractory Aggressive B-Cell Lymphomas
Sanjal Desai, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Lectures

Virologic Clearance of Hepatitis C Is Associated with Improved Outcomes in African American Patients with Lymphoma
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019